CLINUVEL PHARMACEUTICALS LIMITED - Announcements

2.07%

$12.34

Market Cap $619.2M

Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on... Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.More

ASX:AFP

Could this ASX stock become the next Pfizer? A look at AFT Pharmaceuticals (ASX:AFP). With biotech stocks broadly having a strong run in 2025, and with more of the year ahead, investors are still looking for stocks in the sector with room to run. Latest:...

Announcements

Filter Results

All Price Sensitive Only

CUV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	347.86KB	Share
CUV	Results of Meeting		26/10/22	144.34KB	Share
CUV	Chair Address		26/10/22	321.32KB	Share
CUV	Melbourne Investor Briefing Presentation		21/10/22	2.68MB	Share
CUV	First vitiligo patient enrolled in monotherapy study		20/10/22	151.05KB	Share
CUV	Investor Presentation - Sydney		14/10/22	3.31MB	Share
CUV	Notice of Annual General Meeting/Proxy Form		23/09/22	3.86MB	Share
CUV	Strategic Update V		19/09/22	408.93KB	Share
CUV	Presentation - HC Wainright Global Investment Conference		13/09/22	869KB	Share
CUV	Annual General Meeting Date		08/09/22	391.42KB	Share
CUV	CLINUVEL submits label expansion for adolescent EPP patients		05/09/22	157.73KB	Share
CUV	S&P DJI Announces September 2022 Quarterly Rebalance	PRICE SENSITIVE	02/09/22	134KB	Share
CUV	CLINUVEL Investor Webinar Financial Results 2022		31/08/22	2.1MB	Share
CUV	Appendix 4G and Corporate Governance Statement		30/08/22	2.57MB	Share
CUV	Revenue Growth Drives CLINUVEL's Full Year Profit		30/08/22	309.29KB	Share
CUV	Dividend/Distribution - CUV		30/08/22	22.38KB	Share
CUV	Appendix 4E and Annual Report 2022	PRICE SENSITIVE	30/08/22	17.97MB	Share
CUV	CLINUVEL Newsletter IV - August 2022		23/08/22	441.77KB	Share
CUV	Chair's Letter		05/08/22	190.08KB	Share
CUV	PRENUMBRA Instant Formulation for Stroke		28/07/22	164.02KB	Share
CUV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	25/07/22	249.09KB	Share
CUV	Change of Director's Interest Notice		23/06/22	230.56KB	Share
CUV	CLINUVEL Newsletter III - June 2022		23/06/22	695.71KB	Share
CUV	Change of Director's Interest Notice		14/06/22	230.59KB	Share
CUV	Ceasing to be a substantial holder		14/06/22	1.1MB	Share
CUV	H.C. Wainwright Global Investment Conference Presentation		26/05/22	661.41KB	Share
CUV	Change in substantial holding		25/05/22	1.24MB	Share
CUV	Becoming a substantial holder		20/05/22	1.58MB	Share
CUV	CLINUVEL Strategic Update IV - May 2022		13/05/22	127.21KB	Share
CUV	Change of Director's Interest Notice x 2		12/05/22	273.41KB	Share
CUV	CLINUVEL Progresses CUV104 Vitiligo Study		10/05/22	138.18KB	Share
CUV	Notification regarding unquoted securities - CUV		06/05/22	25.32KB	Share
CUV	Positive Final Results in Stroke Study CUV801	PRICE SENSITIVE	04/05/22	327.4KB	Share
CUV	CEO Letter		29/04/22	242.37KB	Share
CUV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/22	371.79KB	Share
CUV	Notice of ceasing to be a substantial holder		27/04/22	465.97KB	Share
CUV	Initial Director's Interest Notice		07/04/22	161.53KB	Share
CUV	Chair's Letter		06/04/22	184.17KB	Share
CUV	CLINUVEL appoints new Non-Executive Director		04/04/22	107.45KB	Share
CUV	CLINUVEL Extends CEO Employment Agreement		01/04/22	2.1MB	Share
CUV	CLINUVEL Newsletter II - March 2022		31/03/22	2.48MB	Share
CUV	First XP-V Patient Treated in Third CUV DNA Repair Study		30/03/22	148.69KB	Share
CUV	Change of Director's Interest Notice		23/03/22	314.8KB	Share
CUV	ACTH Manufacturing Update	PRICE SENSITIVE	17/03/22	201.09KB	Share
CUV	afamelanotide in Stroke (AIS) - Positive Preliminary Results	PRICE SENSITIVE	15/03/22	207.06KB	Share
CUV	Change of Director's Interest Notice		02/03/22	251.5KB	Share
CUV	CEO Letter		28/02/22	324.65KB	Share
CUV	CLINUVEL Reports December Half Year Operating Results	PRICE SENSITIVE	23/02/22	97.26KB	Share
CUV	Appendix 4D Half Year Report	PRICE SENSITIVE	23/02/22	974.45KB	Share
CUV	Operations Update I Financial Results Webinar		16/02/22	151.05KB	Share
CUV	CLINUVEL Expands DNA Repair Program with 2nd Study		14/02/22	125.5KB	Share
CUV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	281.53KB	Share
CUV	CLINUVEL Newsletter I - January 22		27/01/22	482.43KB	Share
CUV	SCENESSE Continued in Germany		24/01/22	110.19KB	Share
CUV	Change of Director's Interest Notice		19/01/22	231.08KB	Share
CUV	Notification of cessation of securities - CUV		19/01/22	21.49KB	Share
CUV	CLINUVEL completes enrolment in CUV801 Stroke Study		17/01/22	142.76KB	Share
CUV	Presentation - H.C. Wainwright Bioconnect Conference 2022		10/01/22	876.19KB	Share
CUV	Progress update to DNA Repair Program		23/12/21	112.53KB	Share
CUV	Chair Letter		21/12/21	996.82KB	Share
CUV	CLINUVEL Newsletter 6 - December 2021		20/12/21	148.49KB	Share
CUV	CLINUVEL Study to Evaluate SCENESSE as Vitiligo Monotherapy		20/12/21	106.39KB	Share
CUV	CLINUVEL Newsletter 5 - November 2021		22/11/21	355.86KB	Share
CUV	Presentation Jefferies London Healthcare Conference		18/11/21	777.71KB	Share
CUV	Results of Meeting		11/11/21	142.94KB	Share
CUV	Managing Director AGM Presentation		10/11/21	3.09MB	Share
CUV	Chair Address		10/11/21	110.66KB	Share
CUV	CLINUVEL Strategic Update III - November 2021		08/11/21	166.34KB	Share
CUV	Media release - CLINUVEL Expands Pharmaceutical Portfolio		08/11/21	295.65KB	Share
CUV	CLINUVEL adds ACTH to portfolio		08/11/21	382.63KB	Share
CUV	Response to ASX Price Query	PRICE SENSITIVE	08/11/21	257.36KB	Share
CUV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	203.94KB	Share
CUV	CLINUVEL Investor Webinar Released		26/10/21	113.74KB	Share
CUV	First Patient Treated in CLINUVEL DNA Repair Study		22/10/21	133.25KB	Share
CUV	Investor Webinar		18/10/21	121.42KB	Share
CUV	Appendix 4G and Corporate Governance Statement		08/10/21	489.02KB	Share
CUV	Notice of Annual General Meeting/Proxy Form		08/10/21	443.89KB	Share
CUV	Annual Report to shareholders		08/10/21	6.09MB	Share
CUV	Operations Update Webcast II		07/10/21	80.98KB	Share
CUV	CLINUVEL Progresses DNA Repair Program		05/10/21	160.99KB	Share
CUV	CLINUVEL Key Events and Announcements		23/09/21	214.87KB	Share
CUV	CLINUVEL Confirms AGM Date		22/09/21	150.2KB	Share
CUV	Notification regarding unquoted securities - CUV		16/09/21	26.63KB	Share
CUV	Presentation H.C. Wainwright Global Investment Conference		14/09/21	544.58KB	Share
CUV	CLINUVEL Investor Webinar Financial Results		27/08/21	521.9KB	Share
CUV	Dividend/Distribution - CUV		26/08/21	22.39KB	Share
CUV	CLINUVEL Newsletter 4 - August 2021		26/08/21	441.51KB	Share
CUV	Corporate Presentation - FY2021 Results		26/08/21	673.08KB	Share
CUV	CLINUVEL Delivers Record Revenues and Profit	PRICE SENSITIVE	26/08/21	407.94KB	Share
CUV	Appendix 4E and Preliminary Financial Report	PRICE SENSITIVE	26/08/21	1.63MB	Share
CUV	Afamelanotide well tolerated by first stroke patients		10/08/21	346.98KB	Share
CUV	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/21	351.59KB	Share
CUV	Change of Director's Interest Notice		05/07/21	259.65KB	Share
CUV	Change of Director's Interest Notice		29/06/21	231.07KB	Share
CUV	Media release - First stroke patient with afamelanotide		07/06/21	173.47KB	Share
CUV	First stroke patient treated with afamelanotide		07/06/21	410.6KB	Share
CUV	CLINUVEL Presentation to Jefferies Healthcare Conference		04/06/21	167.79KB	Share
CUV	CLINUVEL Newsletter 3 - June 2021		03/06/21	1.01MB	Share
CUV	Change of Director's Interest Notice		01/06/21	259.56KB	Share
CUV	Chair's Letter II		31/05/21	217.92KB	Share

CUV Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	347.86KB	Share
CUV Results of Meeting
26/10/22		144.34KB	Share
CUV Chair Address
26/10/22		321.32KB	Share
CUV Melbourne Investor Briefing Presentation
21/10/22		2.68MB	Share
CUV First vitiligo patient enrolled in monotherapy study
20/10/22		151.05KB	Share
CUV Investor Presentation - Sydney
14/10/22		3.31MB	Share
CUV Notice of Annual General Meeting/Proxy Form
23/09/22		3.86MB	Share
CUV Strategic Update V
19/09/22		408.93KB	Share
CUV Presentation - HC Wainright Global Investment Conference
13/09/22		869KB	Share
CUV Annual General Meeting Date
08/09/22		391.42KB	Share
CUV CLINUVEL submits label expansion for adolescent EPP patients
05/09/22		157.73KB	Share
CUV S&P DJI Announces September 2022 Quarterly Rebalance
02/09/22	PRICE SENSITIVE	134KB	Share
CUV CLINUVEL Investor Webinar Financial Results 2022
31/08/22		2.1MB	Share
CUV Appendix 4G and Corporate Governance Statement
30/08/22		2.57MB	Share
CUV Revenue Growth Drives CLINUVEL's Full Year Profit
30/08/22		309.29KB	Share
CUV Dividend/Distribution - CUV
30/08/22		22.38KB	Share
CUV Appendix 4E and Annual Report 2022
30/08/22	PRICE SENSITIVE	17.97MB	Share
CUV CLINUVEL Newsletter IV - August 2022
23/08/22		441.77KB	Share
CUV Chair's Letter
05/08/22		190.08KB	Share
CUV PRENUMBRA Instant Formulation for Stroke
28/07/22		164.02KB	Share
CUV Quarterly Activities/Appendix 4C Cash Flow Report
25/07/22	PRICE SENSITIVE	249.09KB	Share
CUV Change of Director's Interest Notice
23/06/22		230.56KB	Share
CUV CLINUVEL Newsletter III - June 2022
23/06/22		695.71KB	Share
CUV Change of Director's Interest Notice
14/06/22		230.59KB	Share
CUV Ceasing to be a substantial holder
14/06/22		1.1MB	Share
CUV H.C. Wainwright Global Investment Conference Presentation
26/05/22		661.41KB	Share
CUV Change in substantial holding
25/05/22		1.24MB	Share
CUV Becoming a substantial holder
20/05/22		1.58MB	Share
CUV CLINUVEL Strategic Update IV - May 2022
13/05/22		127.21KB	Share
CUV Change of Director's Interest Notice x 2
12/05/22		273.41KB	Share
CUV CLINUVEL Progresses CUV104 Vitiligo Study
10/05/22		138.18KB	Share
CUV Notification regarding unquoted securities - CUV
06/05/22		25.32KB	Share
CUV Positive Final Results in Stroke Study CUV801
04/05/22	PRICE SENSITIVE	327.4KB	Share
CUV CEO Letter
29/04/22		242.37KB	Share
CUV Quarterly Activities/Appendix 4C Cash Flow Report
28/04/22	PRICE SENSITIVE	371.79KB	Share
CUV Notice of ceasing to be a substantial holder
27/04/22		465.97KB	Share
CUV Initial Director's Interest Notice
07/04/22		161.53KB	Share
CUV Chair's Letter
06/04/22		184.17KB	Share
CUV CLINUVEL appoints new Non-Executive Director
04/04/22		107.45KB	Share
CUV CLINUVEL Extends CEO Employment Agreement
01/04/22		2.1MB	Share
CUV CLINUVEL Newsletter II - March 2022
31/03/22		2.48MB	Share
CUV First XP-V Patient Treated in Third CUV DNA Repair Study
30/03/22		148.69KB	Share
CUV Change of Director's Interest Notice
23/03/22		314.8KB	Share
CUV ACTH Manufacturing Update
17/03/22	PRICE SENSITIVE	201.09KB	Share
CUV afamelanotide in Stroke (AIS) - Positive Preliminary Results
15/03/22	PRICE SENSITIVE	207.06KB	Share
CUV Change of Director's Interest Notice
02/03/22		251.5KB	Share
CUV CEO Letter
28/02/22		324.65KB	Share
CUV CLINUVEL Reports December Half Year Operating Results
23/02/22	PRICE SENSITIVE	97.26KB	Share
CUV Appendix 4D Half Year Report
23/02/22	PRICE SENSITIVE	974.45KB	Share
CUV Operations Update I Financial Results Webinar
16/02/22		151.05KB	Share
CUV CLINUVEL Expands DNA Repair Program with 2nd Study
14/02/22		125.5KB	Share
CUV Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	281.53KB	Share
CUV CLINUVEL Newsletter I - January 22
27/01/22		482.43KB	Share
CUV SCENESSE Continued in Germany
24/01/22		110.19KB	Share
CUV Change of Director's Interest Notice
19/01/22		231.08KB	Share
CUV Notification of cessation of securities - CUV
19/01/22		21.49KB	Share
CUV CLINUVEL completes enrolment in CUV801 Stroke Study
17/01/22		142.76KB	Share
CUV Presentation - H.C. Wainwright Bioconnect Conference 2022
10/01/22		876.19KB	Share
CUV Progress update to DNA Repair Program
23/12/21		112.53KB	Share
CUV Chair Letter
21/12/21		996.82KB	Share
CUV CLINUVEL Newsletter 6 - December 2021
20/12/21		148.49KB	Share
CUV CLINUVEL Study to Evaluate SCENESSE as Vitiligo Monotherapy
20/12/21		106.39KB	Share
CUV CLINUVEL Newsletter 5 - November 2021
22/11/21		355.86KB	Share
CUV Presentation Jefferies London Healthcare Conference
18/11/21		777.71KB	Share
CUV Results of Meeting
11/11/21		142.94KB	Share
CUV Managing Director AGM Presentation
10/11/21		3.09MB	Share
CUV Chair Address
10/11/21		110.66KB	Share
CUV CLINUVEL Strategic Update III - November 2021
08/11/21		166.34KB	Share
CUV Media release - CLINUVEL Expands Pharmaceutical Portfolio
08/11/21		295.65KB	Share
CUV CLINUVEL adds ACTH to portfolio
08/11/21		382.63KB	Share
CUV Response to ASX Price Query
08/11/21	PRICE SENSITIVE	257.36KB	Share
CUV Quarterly Activities/Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	203.94KB	Share
CUV CLINUVEL Investor Webinar Released
26/10/21		113.74KB	Share
CUV First Patient Treated in CLINUVEL DNA Repair Study
22/10/21		133.25KB	Share
CUV Investor Webinar
18/10/21		121.42KB	Share
CUV Appendix 4G and Corporate Governance Statement
08/10/21		489.02KB	Share
CUV Notice of Annual General Meeting/Proxy Form
08/10/21		443.89KB	Share
CUV Annual Report to shareholders
08/10/21		6.09MB	Share
CUV Operations Update Webcast II
07/10/21		80.98KB	Share
CUV CLINUVEL Progresses DNA Repair Program
05/10/21		160.99KB	Share
CUV CLINUVEL Key Events and Announcements
23/09/21		214.87KB	Share
CUV CLINUVEL Confirms AGM Date
22/09/21		150.2KB	Share
CUV Notification regarding unquoted securities - CUV
16/09/21		26.63KB	Share
CUV Presentation H.C. Wainwright Global Investment Conference
14/09/21		544.58KB	Share
CUV CLINUVEL Investor Webinar Financial Results
27/08/21		521.9KB	Share
CUV Dividend/Distribution - CUV
26/08/21		22.39KB	Share
CUV CLINUVEL Newsletter 4 - August 2021
26/08/21		441.51KB	Share
CUV Corporate Presentation - FY2021 Results
26/08/21		673.08KB	Share
CUV CLINUVEL Delivers Record Revenues and Profit
26/08/21	PRICE SENSITIVE	407.94KB	Share
CUV Appendix 4E and Preliminary Financial Report
26/08/21	PRICE SENSITIVE	1.63MB	Share
CUV Afamelanotide well tolerated by first stroke patients
10/08/21		346.98KB	Share
CUV Quarterly Activities/Appendix 4C Cash Flow Report
29/07/21	PRICE SENSITIVE	351.59KB	Share
CUV Change of Director's Interest Notice
05/07/21		259.65KB	Share
CUV Change of Director's Interest Notice
29/06/21		231.07KB	Share
CUV Media release - First stroke patient with afamelanotide
07/06/21		173.47KB	Share
CUV First stroke patient treated with afamelanotide
07/06/21		410.6KB	Share
CUV CLINUVEL Presentation to Jefferies Healthcare Conference
04/06/21		167.79KB	Share
CUV CLINUVEL Newsletter 3 - June 2021
03/06/21		1.01MB	Share
CUV Change of Director's Interest Notice
01/06/21		259.56KB	Share
CUV Chair's Letter II
31/05/21		217.92KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $12.34		Change 0.250(2.07%)		Mkt cap ! $619.2M

Open	High	Low	Value	Volume
$12.09	$12.43	$11.96	$944.0K	76.95K

Buyers (Bids)

No.	Vol.	Price($)
1	8	$12.34

Sellers (Offers)

Price($)	Vol.	No.
$12.35	1203	3

View Market Depth

No.	Vol.	Price($)
12	294	12.340
5	2561	12.330
4	453	12.320
3	384	12.310
3	369	12.300

Price($)	Vol.	No.
12.380	885	9
12.390	318	4
12.400	3903	2
12.410	206	2
12.420	420	3

Last trade - 15.45pm 13/08/2025 (20 minute delay)


Last $12.36		Change 0.250 ( 2.12 %)
Open	High	Low	Volume
$12.12	$12.42	$12.08	18070
Last updated 15.59pm 13/08/2025 ?

CUV (ASX) Chart

CLINUVEL PHARMACEUTICALS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories